ARID1A — gene · CancerIndex

Curated evidence

Clinical evidence (14)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–14 of 14 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ARID1A Loss5
(oncogenic)	Ovarian Clear Cell Adenocarcinoma	Oncogenic	B	Supports Oncogenicity	4	submitted	EID13135 Ovarian clear cell carcinoma is a relatively chemotherapy-refractory ovarian cancer subtype with a comparatively stable genome and a well-recognized association with endometriosis, but the somatic alt…

Cohorts

Alteration frequency by cohort (200)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved200 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017) egc_msk_2017	Gastroesophageal Junction Adenocarcinoma	Ssm

Literature

Linked publications (6)

25 per page, newest first.

pubmedPublishedShowing 1–6 of 6 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma.
· Hum Pathol · 2015 · PMID 25628030 · validated civic_curation pubmed
Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
· Mod Pathol · 2012 · PMID 22101352 · validated civic_curation pubmed
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
· Gynecol Oncol · 2023 · PMID 37418832 · validated civic_curation pubmed
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
· Nat Med · 2015 · PMID 25686104 · validated

ARID1A Underexpression3
(prognostic)	Clear Cell Renal Cell Carcinoma	Prognostic	B	Supports Poor Outcome	3	accepted	EID5676 This study included 290 patients with Clear Cell Renal Cell Carcinoma whose tumor tissues were sampled and then analyzed. These samples were then divided according to ARID1A expression after immunohis… (full text at CIViC) PMID 25628030 · Park et al., 2015 · Open in CIViC	civic
〃	Ovarian Clear Cell CarcinomaUNRESOLVED	Prognostic	B	Supports Poor Outcome	3	accepted	EID5787 In a study of 60 individuals with ovarian clear cell carcinoma, ARID1A expression was analyzed using immunohistochemistry. Of these 60 patients, 9 (15%) patients had a loss of ARID1A expression. Resul… (full text at CIViC) PMID 22101352 · Katagiri et al., 2012 · Open in CIViC	civic
〃	Malignant Gastric Neoplasm	Prognostic	D	Supports Poor Outcome	4	accepted	EID5675 In this study, real-time quantitative RT-PCR assays were used in 66 pairs of cancerous and matched adjacent normal tissues. In 43 of those pairs, the expression level of ARID1A was significantly lower… (full text at CIViC) PMID 22808142 · Wang et al., 2012 · Open in CIViC	civic